MedTrace Logo

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

NCT02085798 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 503

Last updated 2020-01-27

No results posted yet for this study

Summary

Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment when active treatment is initiated. Subjects will be recruited from approximately 50 haematology sites in Spain.

Conditions

Interventions

OTHER

Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion

As described above

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Montserrat Rafel, RML Advocacy · Celgene Spain

  • Regina Garcia, MD · Hospital Clínico Virgen de la Victoria, Málaga, Spain

  • David Valcárcel, MD · Hospital Vall d'Hebron, Barcelona, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-17
Primary Completion
2015-08-31
Completion
2018-12-14

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02085798 on ClinicalTrials.gov